- Conditions
- Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Danbury, Connecticut + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–67
of 67
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dimethyl Fumarate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Seattle, Washington
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- BeCare application
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Vatelizumab, Placebo (for Vatelizumab)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 12
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Placebo, Ocrelizumab, Avonex
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Ofatumumab, Disease modifying treatment (DMT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Chandler, Arizona + 34 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- San Bernardino, California
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon beta 1a, oral doxycycline
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Shreveport, Louisiana
- Conditions
- Multiple Sclerosis
- Interventions
- Laquinimod, Placebo, Avonex®
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Multiple Sclerosis Functional Composite, Mobile Multiple Sclerosis Functional Composite
- Procedure
- Lead sponsor
- Transparency Life Sciences
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 52
- States / cities
- Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- BAF312
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 8
- States / cities
- Miami, Florida • Pompano Beach, Florida • Tallahassee, Florida + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises
- Behavioral
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- East Hanover, New Jersey • Marlton, New Jersey
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- MSDX Complex-1 Biomarker test
- Other
- Lead sponsor
- MSDx, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- fingolimod, glatiramer acetate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 101
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- John F. Foley, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- dimethyl fumarate
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Loma Linda, California